Xcout Intel
Exagen Inc.
Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients. The company's product portfolio includes AVISE Lupus, which assesses complement system activation by measuring B-cell C4d and erythrocyte-bound C4d in blood. AVISE APS offers a comprehensive panel of autoantibody tests for the diagnosis and management of Antiphospholipid Syndrome (APS). For SLE patients, AVISE SLE Prognostic provides an autoantibody panel to evaluate the potential for kidney, brain, and cardiovascular complications. Additionally, AVISE Vasculitis AAV utilizes a testing panel of individual analytes to assist physicians in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, while AVISE Anti-CarP helps identify RA patients prone to severe disease, and AVISE PC4d measures platelet-bound C4d. Further offerings include AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, designed to monitor hydroxychloroquine levels. Exagen also holds a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to advance the development of novel patented biomarkers. Incorporated in 2002, the company was formerly known as Exagen Diagnostics, Inc. before rebranding to Exagen Inc. in January 2019. Its headquarters are located in Vista, California.
Subscribe to see Exagen Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Exagen Inc. at a glance
Exagen Inc. is a biotechnology company headquartered in Vista, United States. It is publicly listed (XGN) with a market capitalisation of $113.1M. Xcout tracks 33 named people at Exagen Inc., including John Aballi (Chief Executive Officer, President & Director).
Exagen Inc. leadership
- John AballiChief Executive Officer, President & Director
- Fortunato Ron RoccaPresident and Chief Executive Officer
- Jeffrey G. BlackChief Financial Officer & Corporate Secretary
- Jeff BlackChief Financial Officer
- Kamal AdawiChief Financial Officer
- Prashanti ReddyChief Medical Officer
27 more named people on record for Exagen Inc., with roles, board committees and tenure — see the full roster →
Get Exagen Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Exagen Inc. in Xcout Intel
- 33 named people with titles, LinkedIn and board committees
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access